-
Sanofi gets tentative FDA approval for Humalog follow-on Admelog
SILVER SPRING, Md. — The Food and Drug Administration recently granted tentative approval to Sanofi’s Admelog (insulin lispro injection, 100 units/ml), a rapid-acting human insulin analog. The drug, a follow-on biologic version of Lilly’s Humalog, is indicated to improve glycemic control in patients with diabetes.The approval means that Admelog has met all requirements for the regulatory agency, pending any patent issues that have not yet been resolved.XThis ad will auto-close in 10 seconds